Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Mathieu Beauregard

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 9, 2022
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancerJean-Mathieu Beauregard
European Journal of Nuclear Medicine and Molecular Imaging|November 13, 2021
Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)Jean-Mathieu Beauregard, Arman Rahmim
Current Opinion in Supportive and Palliative Care|July 9, 2014
New developments in the imaging of metastatic prostate cancerJean-Mathieu Beauregard, Frédéric Pouliot
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 8, 2016
How we read FCH-PET/CT for prostate cancerJean-Mathieu Beauregard, Alexis Beaulieu
Current Opinion in Supportive and Palliative Care|June 26, 2018
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapyFrédéric Arsenault, Jean-Mathieu Beauregard, Frédéric Pouliot
European Urology Focus|June 23, 2026
How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?Jean-Mathieu Beauregard, Michael Ong, Frédéric Pouliot
PET Clinics|May 10, 2016
Steroid Receptor Imaging in Breast CancerJean-Mathieu Beauregard, Éric Turcotte, François Bénard
European Journal of Nuclear Medicine and Molecular Imaging|September 8, 2019
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumoursSamuel Adant, Girish M Shah, Jean-Mathieu Beauregard
Physics in Medicine and Biology|August 29, 2019
Personalized kidney dosimetry in <sup>177</sup>Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentationsXinchi Hou, Wei Zhao, Jean-Mathieu Beauregard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 1, 2017
Personalized <sup>177</sup>Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation studyMichela Del Prete, François-Alexandre Buteau, Jean-Mathieu Beauregard
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 9, 2022
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancerJean-Mathieu Beauregard
European Journal of Nuclear Medicine and Molecular Imaging|November 13, 2021
Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)Jean-Mathieu Beauregard, Arman Rahmim
Current Opinion in Supportive and Palliative Care|July 9, 2014
New developments in the imaging of metastatic prostate cancerJean-Mathieu Beauregard, Frédéric Pouliot
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 8, 2016
How we read FCH-PET/CT for prostate cancerJean-Mathieu Beauregard, Alexis Beaulieu
Current Opinion in Supportive and Palliative Care|June 26, 2018
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapyFrédéric Arsenault, Jean-Mathieu Beauregard, Frédéric Pouliot
European Urology Focus|June 23, 2026
How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?Jean-Mathieu Beauregard, Michael Ong, Frédéric Pouliot
PET Clinics|May 10, 2016
Steroid Receptor Imaging in Breast CancerJean-Mathieu Beauregard, Éric Turcotte, François Bénard
European Journal of Nuclear Medicine and Molecular Imaging|September 8, 2019
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumoursSamuel Adant, Girish M Shah, Jean-Mathieu Beauregard
Physics in Medicine and Biology|August 29, 2019
Personalized kidney dosimetry in <sup>177</sup>Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentationsXinchi Hou, Wei Zhao, Jean-Mathieu Beauregard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 1, 2017
Personalized <sup>177</sup>Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation studyMichela Del Prete, François-Alexandre Buteau, Jean-Mathieu Beauregard
Pageof 7